NeurAxis (NASDAQ:NRXS – Get Free Report) and Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Valuation and Earnings
This table compares NeurAxis and Heyu Biological Technology’s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
NeurAxis | $2.27 million | 9.33 | -$14.63 million | ($3.73) | -0.85 |
Heyu Biological Technology | $80,000.00 | 451.71 | -$270,000.00 | N/A | N/A |
Heyu Biological Technology has lower revenue, but higher earnings than NeurAxis.
Profitability
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -633.10% | N/A | -926.02% |
Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
Analyst Ratings
This is a summary of current ratings and target prices for NeurAxis and Heyu Biological Technology, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
Heyu Biological Technology | 0 | 0 | 0 | 0 | N/A |
Insider & Institutional Ownership
11.8% of NeurAxis shares are held by institutional investors. 15.2% of NeurAxis shares are held by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Heyu Biological Technology beats NeurAxis on 5 of the 9 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.